<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73994">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02065843</url>
  </required_header>
  <id_info>
    <org_study_id>ANSI-388.427</org_study_id>
    <nct_id>NCT02065843</nct_id>
  </id_info>
  <brief_title>Three Anxiolytic Drugs Used in Third Molar Surgery</brief_title>
  <official_title>Comparative Study of the Effectiveness of Three Anxiolytic Drugs Used in Third Molar Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal de Sergipe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal de Sergipe</source>
  <oversight_info>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was to compare the effectiveness of three drugs (Passiflora incarnata, Erythrina
      mulungum, Midazolam)  in controlling anxiety in patients undergoing bilateral extraction of
      asymptomatic, impacted mandibular third molars.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this research, characterized as a randomized, double-blind, parallel study, 200 healthy
      volunteered patients aging 18 or older will be distributed into 4 groups (n=50) as follows:
      Group I - 500mg Erythrina mulungu; Group II - placebo; Group III ; 100 mg Passiflora
      incarnata; Group IV - 15 mg midazolam. All treatments will be administered p.o. 1 hour
      randomly prior to the surgical procedures. The level of anxiety will be assessed through
      questionnaires and physical parameters, such as blood pressure, heart rate and oxygen
      concentration in three periods: at baseline, right before the surgical procedures and after
      7 days. Data will be collected, tabulated and analyzed by the following statistical tests:
      chi-square, t-test, ANOVA and Tukey test, Friedman, Fisher's exact test with significance
      level of 5%.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in anxiety report</measure>
    <time_frame>Change from baseline to 7 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Changes in the subjects' anxiety level will be observed by using a Modified Corah Dental Anxiety Scale in three times: at baseline, in the day of surgery and after 7 days of the procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in blood pressure</measure>
    <time_frame>Change from baseline to 2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>blood pressure (mmHg) will be measured before the drugs administration, 30 minutes after drugs administration and during local anesthesia, incision, tooth removal and suturing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in heart rate</measure>
    <time_frame>Change from baseline to 2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>heart rate (bpm) will be measured before drugs administration, 30 minutes after drugs administration and during local anesthesia, incision, tooth removal and suturing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in oxygen saturation</measure>
    <time_frame>Change from baseline to 2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>oxygen saturation (SpO2) will be measured before drugs administration, 30 minutes after drugs administration and during local anesthesia, incision, tooth removal and suturing.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Dental Anxiety</condition>
  <condition>Impacted Third Molar Tooth</condition>
  <arm_group>
    <arm_group_label>Mulungu</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg Mulungu MatusaÂ® (Erytrina mulungu, 2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>500 mg of starch (2 capsules of 250 mg) to be administered v.o., one hour before the surgical procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Passiflora incarnata</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>100 mg Passiflora incarnata (2 capsules of 50 mg) to be administered v.o., one hour before the surgical procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>15 mg  midazolam (2 capsules of 7.5 mg) to be administered v.o., one hour before the surgical procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mulungu</intervention_name>
    <description>500 mg/single dose/1 hour before dental surgery</description>
    <arm_group_label>Mulungu</arm_group_label>
    <other_name>Mulungu Matusa, Erytrina mulungu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>500 mg/single dose/1 hour before dental surgery</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Passiflora incarnata</intervention_name>
    <description>100 mg/single dose/1 hour before dental surgery</description>
    <arm_group_label>Passiflora incarnata</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>midazolam</intervention_name>
    <description>15 mg/single dose/1 hour before dental surgery</description>
    <arm_group_label>midazolam</arm_group_label>
    <other_name>Dormonid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  indication of bilateral extraction of asymptomatic, impacted mandibular third molars

        Exclusion Criteria:

          -  patients under the age of 18 any general health problem based on the medical history
             and physical examination history of use of any medication within 15 days before the
             beginning of the research history of hypersensitivity to drugs, substances or
             materials used in this experiment pregnancy or lactation history of pericoronitis
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liane M Souza, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Federal University of Sergipe</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liane M Souza, PhD</last_name>
    <phone>+557999777001</phone>
    <email>odontoliu@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francisco C Groppo, PhD</last_name>
    <phone>+551921065310</phone>
    <email>fcgroppo@fop.unicamp.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal University of Sergipe</name>
      <address>
        <city>Aracaju</city>
        <state>Sergipe</state>
        <zip>49060-100</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Liane M Souza, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <reference>
    <citation>Balbani AP, Silva DH, Montovani JC. Patents of drugs extracted from Brazilian medicinal plants. Expert Opin Ther Pat. 2009 Apr;19(4):461-73. doi: 10.1517/13543770902824180. Review.</citation>
    <PMID>19441926</PMID>
  </reference>
  <reference>
    <citation>Flausino OA Jr, Pereira AM, da Silva Bolzani V, Nunes-de-Souza RL. Effects of erythrinian alkaloids isolated from Erythrina mulungu (Papilionaceae) in mice submitted to animal models of anxiety. Biol Pharm Bull. 2007 Feb;30(2):375-8.</citation>
    <PMID>17268084</PMID>
  </reference>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 15, 2014</lastchanged_date>
  <firstreceived_date>February 15, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal de Sergipe</investigator_affiliation>
    <investigator_full_name>Liane Maciel de Almeida Souza</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Anxiety</keyword>
  <keyword>Third molar surgery</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Heart rate</keyword>
  <keyword>Oxygen saturation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Tooth, Impacted</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Anti-Anxiety Agents</mesh_term>
    <mesh_term>Tranquilizing Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
